Business
Commercial Collaboration Progress Update
Commercial Collaboration Progress Update.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n \n28 August 2024\n\nGraft Polymer (UK) Plc\n(the \"Company\")\n \nSubstantial progress in Awakn collaboration\n \nIdentification of lead series, selection of Charnwood Discovery as synthesis partner, and new patent filing\n \n \nGraft Polymer (UK) Plc (LON: GPL), an innovative healthcare services company, is pleased to report substantial progress in its collaboration with Awakn Life Sciences Corp. (CSE: \"AWKN\", OTCQB: AWKNF) (\"Awakn\"), details of which were announced on 18 July 2024.\n \nThe collaboration focuses on developing a new class of therapeutics for the potential treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder (\"PTSD\"), which affects approximately 13 million adults in the U.S. and 20 million collectively in the US and other key international markets.\n \nRecent progress includes:\n \n· Lead chemical series identified: Awakn has successfully identified two aminoindane chemical series as co-leads for further development. These series represent a promising new class of compounds with the potential to improve treatment options for trauma-related mental health disorders such as PTSD. The selection of these lead candidates is a pivotal step in the drug development process.\n \n· Synthesis pathways defined: Awakn has also successfully established synthesis pathways for these compounds. This achievement is crucial, as it enables efficient and scalable production of the drug candidates, which will be essential as the collaboration moves towards more advanced pharmacological testing.\n \n· Charnwood Discovery selected as synthesis partner: Awakn has selected Charnwood Discovery, a respected UK-based provider of drug discovery services, as its synthesis partner. The selection of Charnwood Discovery, known for its technical expertise, ensures that the synthesis process will b...